GlassScriptPhysician profile
Atul M Vaidya
NPI 1649263450
$1,316.55
in general payments reported to CMS, 2019-2025
11 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $154 · 2021: $449 · 2022: $36.25 · 2023: $290 · 2024: $19.60 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $415.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intersect Ent, INC. | $754.57 | 2019-2021 | |
| Acclarent, INC | $130.40 | 2023 | Trudi Nav Cable, Acclarent Aera |
| Medtronic, INC. | $107.68 | 2023 | Alar |
| Stryker Corporation | $78.94 | 2019-2020 | |
| Genzyme Corporation | $59.60 | 2024-2025 | |
| Alk-Abello, INC | $58.11 | 2021-2023 | Grastek, Odactra, Ragwitek |
| Optinose US, INC. | $46.29 | 2019-2025 | |
| Glaxosmithkline, LLC. | $40.48 | 2023-2025 | Nucala |
| Abbott Laboratories | $24.46 | 2025 | Perclose Prostyle |
| Regeneron Healthcare Solutions, INC. | $16.02 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$821,188.50 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.